Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?
about
A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium saltsNeural and mesenchymal stem cells in animal models of Huntington's disease: past experiences and future challengesDissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network BiologyGSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte-neuron interactionsSystems Genetic Analyses Highlight a TGFβ-FOXO3 Dependent Striatal Astrocyte Network Conserved across Species and Associated with Stress, Sleep, and Huntington's DiseaseManifestation of Huntington's disease pathology in human induced pluripotent stem cell-derived neurons.Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models.IP3 accumulation and/or inositol depletion: two downstream lithium's effects that may mediate its behavioral and cellular changes.Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseasesImpact of lithium alone or in combination with haloperidol on oxidative stress parameters and cell viability in SH-SY5Y cell culture.Glycogen synthase kinase 3β suppresses polyglutamine aggregation by inhibiting Vaccinia-related kinase 2 activity.Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease.
P2860
Q26741164-79CCAC3D-4B16-4B88-B8B4-349C85C4D404Q26775932-615168EF-0832-460D-B357-3AF0D7DAC7B0Q33734563-9E3A20F8-BD7D-49D8-B649-B98FA07E71DAQ36002017-662AD478-3813-4459-8CEB-F56E59000F13Q36070777-74DF54E3-0D1D-4023-9C8A-C601E8622842Q36800354-06770E49-50F1-4B95-B544-1F81E71152D2Q36939755-3FB70B88-C23C-4691-AEA7-5383D93065AFQ37650454-71607D57-AC9E-47E4-9E93-161DB92318EEQ38272835-5F7510A4-E0AE-4CD6-9FED-B3CBAC8651F9Q38842712-02260D1F-DEF6-4D93-AE93-AD231F0001BEQ41852916-CFF55951-8EB1-423D-8118-6BD36E9A908FQ45288661-B5F98F8C-10D2-41C1-A0FC-86323433D578
P2860
Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Preclinical and clinical inves ...... disease: what have we learned?
@ast
Preclinical and clinical inves ...... disease: what have we learned?
@en
Preclinical and clinical inves ...... disease: what have we learned?
@nl
type
label
Preclinical and clinical inves ...... disease: what have we learned?
@ast
Preclinical and clinical inves ...... disease: what have we learned?
@en
Preclinical and clinical inves ...... disease: what have we learned?
@nl
prefLabel
Preclinical and clinical inves ...... disease: what have we learned?
@ast
Preclinical and clinical inves ...... disease: what have we learned?
@en
Preclinical and clinical inves ...... disease: what have we learned?
@nl
P2093
P2860
P356
P1476
Preclinical and clinical inves ...... disease: what have we learned?
@en
P2093
Chi-Tso Chiu
De-Maw Chuang
Gabriel R Linares
Hsiao-Mei Liao
Lisa Scheuing
P2860
P304
P356
10.7150/IJBS.9898
P407
P5008
P577
2014-09-10T00:00:00Z